Enfortumab vedotin for cisplatin-ineligible urothelial cancer

Affiliations

Comment

Geraldine Pignot. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):748-749.

doi: 10.1016/S1470-2045(21)00142-X. Epub 2021 May 12.

¹ Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille 13009, France. Electronic address: pignotg@ipc.unicancer.fr.

No abstract available

Conflict of interest statement

I declare no competing interests.

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.